We are committed to the principles of sustainable development. With our products we aim to improve people's quality of life through innovative new medicines in cardiology, oncology and gynecology.


Our Pharmaceuticals division is committed to providing specialty-focused innovative medicines that ensure significant clinical benefit and value, primarily in the therapeutic areas of cardiology, gynecology, diabetes, oncology and ophthalmology. In this way, we are addressing the growing requirements of patients, healthcare providers and regulatory agencies. In India, we have helped address the unmet healthcare needs of patients through the launch of Bayer’s researched and highly innovative products like Xarelto®, Eylea, and Visanne.


Bayer Zydus Pharma

Since 2011, the Pharmaceuticals Division in India has been operating as Bayer Zydus Pharma. The company focuses on prescription products, especially for cardiology, diabetology, women’s healthcare and on specialty therapeutics in the areas of oncology and ophthalmology. Click here to learn more about Bayer Zydus Pharma.


Bayer For Women

Bayer is one of the true pioneers in the field of women's health globally with almost nine decades of experience - from the launch of the first contraceptive pill, to addressing needs for diseases such as endometriosis in the gynecology field. We remain committed to the principles of sustainable development and continue to improve people’s quality of life with our products.


In Indian society, the woman is the pillar of the family and her well-being matters. However, currently, women’s health in the country remains a primary concern with a lack of access to credible and reliable information and undiagnosed diseases in India. At Bayer, we believe that every woman should be empowered to make informed choices for her health to lead a better life.


Our initiatives engage relevant stakeholders like healthcare practitioners, patients, media, NGO’s etc. to partner in raising awareness on women’s health. We also work closely with the Federation of Obstetric and Gynaecological Societies of India (FOGSI) on various campaigns to develop disease management modules, educate healthcare professionals and raise public awareness on women’s health topics like contraception, PCOS (polycystic ovary syndrome) management and endometriosis.



We have a comprehensive Pharmacovigilance process which constantly monitors drugs and devices throughout their whole lifecycle as well as the effect they have on patients. Bayer has over 1,000 pharmacovigilance experts across the globe who analyze side effects and develop measures to minimize or even prevent them. In a nutshell, they constantly keep an eye on the safety of patients who use our products. Click here to report a side effect